The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of pralsetinib in patients with advanced RET-fusion-positive NSCLC: Final data from the phase 1/2 ARROW study.
 
Gilberto Lopes
Stock and Other Ownership Interests - Biomab; CDR-Life; Lucence Diagnostics; Morphometrix; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Dr. Reddy's Laboratories; Janssen; Merck; Rigel
Consulting or Advisory Role - AstraZeneca; Coherus Biosciences; Dr. Reddy's Laboratories; Mirati Therapeutics; Pfizer; Regeneron
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; BeiGene; Boehringer Ingelheim; Celgene; Coherus Biosciences; Dr. Reddy's Laboratories; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
 
Justin Gainor
Employment - Ironwood Pharmaceuticals (I)
Leadership - AI Proteins, Inc
Stock and Other Ownership Interests - AI Proteins, Inc; Ironwood Pharmaceuticals (I)
Honoraria - BeiGene; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Arcus Biosciences; Array BioPharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ellipses Pharma; EMD Serono; Genentech; Gilead Sciences; InterVenn Biosciences; ITeos Therapeutics; Lilly; Mariana Oncology; Merck; Merus; Mirati Therapeutics; Moderna Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Revolution Medicines; Sanofi; Silverback Therapeutics; Takeda; Tempus
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis; Novartis (Inst); Palleon Pharmaceuticals (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Vivek Subbiah
Consulting or Advisory Role - AADi; Abbvie (Inst); Bayer (Inst); Foundation Medicine; Illumina; Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Other Relationship - Clinical Care Options; Medscape
 
Daniel Bowles
No Relationships to Disclose
 
Robert Doebele
Employment - Rain Oncology
Leadership - Rain Oncology
Stock and Other Ownership Interests - Rain Oncology
Consulting or Advisory Role - EvextaBio; Guardant Health; Pathos AI
Patents, Royalties, Other Intellectual Property - Licensing fees from Casma Therapeutics for Biologic Materials.; Licensing fees from Foundation Medicine for Biologic Materials.; Licensing fees from Loxo for Biologic Materials; Licensing fees from Personal Genome Diagnostics, Inc for Biologic Materials.; Licensing fees from Roche for Biologic Materials.; Licensing fees from Takeda for Biologic Materials; Licensing fees from ThermoFisher for Biologic Materials
Travel, Accommodations, Expenses - Pathos AI
 
Aaron Mansfield
Honoraria - Roche
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Genzyme (Inst); Gilead Sciences (Inst); Janssen (Inst); Johnson & Johnson Global Services (Inst); Takeda (Inst)
Speakers' Bureau - Chugai/Roche (Inst)
Research Funding - Bristol Myers Squibb (Inst); Novartis (Inst); Verily (Inst)
Travel, Accommodations, Expenses - Abbvie; Roche
Other Relationship - Mesothelioma Applied Research Foundation
 
Christina Baik
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Daiichi Sankyo/UCB Japan; Genentech/Roche; Janssen; Natera; Pfizer; Regeneron; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb Foundation (Inst); Daiichi Sankyo (Inst); Ellipses Pharma (Inst); Janssen (Inst); Lilly (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); TP Therapeutics (Inst)
 
Shirish Gadgeel
Consulting or Advisory Role - Abbvie; Arcus Biosciences; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daichii-Sanyko; Eisai; Genentech/Roche; Gilead Sciences; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Merck; Mirati Therapeutics; Pfizer; Regeneron; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avistone Biotechnology (Inst); Bayer (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GRAIL (Inst); Helsinn Therapeutics (Inst); Incyte (Inst); InventisBio (Inst); Iovance Biotherapeutics (Inst); Jacobio (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Kymera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Nimbus Therapeutics (Inst); Novita Pharmaceuticals (Inst); Numab (Inst); Nuvalent, Inc. (Inst); Pfizer (Inst); Regeneron (Inst); Revolution Medicines (Inst); Tango Therapeutics (Inst); Turning Point Therapeutics (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Merck; Mirati Therapeutics
Other Relationship - AstraZeneca
 
Gregory Kalemkerian
Consulting or Advisory Role - BioMed Valley Discoveries (I)
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb Foundation (Inst); Cullinan Oncology (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck (Inst); Takeda (Inst)
 
Sai-Hong Ou
Stock and Other Ownership Interests - BloosomHill therapeutics; Lilly; MBrace Therapeutics; Nuvalent, Inc.; Nuvation Bio
Consulting or Advisory Role - Anheart Therapeutics; Avistone; Bayer; Innovent Biologics; Pfizer
Research Funding - AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); BMS; Janssen (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche Pharma AG (Inst)
 
Carlos Becerra
Consulting or Advisory Role - AstraZeneca; BMS; Ipsen
 
Makenzi Evangelist
Consulting or Advisory Role - AADi; AstraZeneca; AstraZeneca; Daiichi Sankyo/Lilly; Gilead Sciences; Gilead Sciences; Mirati Therapeutics; Regeneron; Regeneron; Takeda; Takeda
 
Stephen Liu
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech; Gilead Sciences; GlaxoSmithKline; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Lilly; Merus; Mirati Therapeutics; MSD Oncology; Natera; Novartis; OSE Immunotherapeutics; Pfizer; RAPT Therapeutics; Regeneron; Revolution Medicines; Takeda; Yuhan
Research Funding - Abbvie (Inst); Alkermes (Inst); AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Cogent Biosciences (Inst); Duality Biologics (Inst); Elevation Oncology (Inst); Ellipses Pharma (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); OSE Immunotherapeutics (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Systimmune (Inst)
(OPTIONAL) Uncompensated Relationships - Roche/Genentech
 
Jason Melear
Consulting or Advisory Role - TG Therapeutics
Speakers' Bureau - AstraZeneca; Janssen; TG Therapeutics
 
Ashish Saxena
Honoraria - Advarra; Galvanize; Galvanize Therapeutics; MJH Healthcare Holdings, LLC; OncLive/MJH Life Sciences; PER
Consulting or Advisory Role - Boehringer Ingelheim; Bristol Myers Squibb; G1 Therapeutics; Galvanize Therapeutics; InxMed; Novocure
Research Funding - Alphamab (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences; Celgene (Inst); Daiichi Sankyo (Inst); Endocyte (Inst); Genentech (Inst); Guardant Health (Inst); Immunomedics (Inst); Jounce Therapeutics (Inst); Merck (Inst); Novocure (Inst); Regeneron (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Top Alliance BioScience (Inst); VM Pharma (Inst)
 
Amber Thomassen
Employment - Rigel
Stock and Other Ownership Interests - Rigel
 
Sophia Wang
Employment - Rigel
Honoraria - Rigel
 
Benjamin Besse
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); Sanofi/Aventis (Inst); SERVIER (Inst)
Consulting or Advisory Role - Abbvie (Inst); beijin avistone (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); CureVac (Inst); Ellipses Pharma (Inst); F. Hoffmann LaRoche (Inst); Foghorn Therapeutics (Inst); Immunocore (Inst); Lilly (Inst); Owkin (Inst); PharmaMar (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); CureVac (Inst); Daiichi Sankyo Europe GmbH (Inst); Enliven Therapeutics (Inst); Genmab (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); OSE Immunotherapeutics (Inst); PharmaMar (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Takeda (Inst)